株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創薬の世界市場の考察・機会分析・市場シェア・将来予測

Global Drug Discovery Market-Technologies, Market share and Industry Forecast to 2024

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 345951
出版日 ページ情報 英文 240 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
創薬の世界市場の考察・機会分析・市場シェア・将来予測 Global Drug Discovery Market-Technologies, Market share and Industry Forecast to 2024
出版日: 2016年03月21日 ページ情報: 英文 240 Pages
概要

創薬および薬剤開発は製薬会社やバイオテクノロジー企業の重要な機能です。創薬プログラムは通常、標的同定、バリデーション、治験、登録、認可などの手続きを経るため、薬剤が正式に上市され市販されるまでに15年の年月を要します。現在、世界の創薬市場では北米企業が最大の市場シェアを有しています。

当レポートでは、世界の創薬市場について調査し、市場の動向と2021年までの収益予測と成長率、業界分析、競合動向、地域別動向、および参入する主要企業のプロファイルをまとめています。

第1章 イントロダクション

第2章 市場概要

  • 主な調査結果
  • バリューチェーン分析
  • 主な購入基準
  • 創薬パイプラインプロセス
    • 標的事前発見
    • 化合物発見
    • リード化合物発見と最適化
    • 事前臨床研究
    • 治験
    • 申請/認可
    • 製造
    • 上市
  • 戦略的提言
  • 戦略的結論
  • 創薬市場における出荷動向
  • 予測動向と新興市場

第3章 市場決定因子

  • 市場促進因子
  • 市場阻害因子
  • 市場の課題
  • 市場の機会

第4章 市場セグメンテーション

  • サービス別
    • 生物学的サービス
    • 化学的サービス
    • 薬学サービス
    • 薬剤代謝・薬物動態サービス
  • 科学別
    • プロテオミクス
    • ゲノミクス
    • バイオインフォマティクス
  • 技術別
    • QPCR
    • DNAおよびタンパク質マイクロアレイ
    • ハイスループットスクリーニング
    • 質量分析
    • ラボ情報管理システム
    • マイクロ流体
    • ゲル電子泳動
    • クロマトグラフィー
    • タンパク質および核酸隔離
    • その他
  • 新規技術

第5章 市場シェアと戦略

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業プロファイリング

  • Sanofi
  • Johnson and Johnson
  • AstraZeneca
  • Bayer
  • BohringerIngheliem
  • Pfizer
  • GlaxoSmithKline
  • Eli Lily
  • Albany Molecular Research
  • Charles River Laboratories
  • Covance
  • Cyprotex
  • EVT innovate
  • Gen Script
  • Pharmaceutical Product Development
  • Quintiles
  • Viva Biotech
  • WIL research Laboratories
  • WUXI Apptech

図表

目次
Product Code: HPH-990915

The market for the global drug discovery is highly affected due to the scientific and technological changes and advancements that are continuously taking place around the world. This market contributes highly in the growth of whole pharmaceutical industry as they help in introduction of new drugs. The global drug discovery market is projected to grow impressive during the forecasted period growing at a CAGR of 9% during 2017-2024. Adoption of global drug discovery market is driven by following factors, such as rising incidences of chronic diseases, rising demand for novel drug discovery technologies and advancement in field of biotechnology. The factors the restrain the growth of the global drug discovery market are the slow growth and development of new drugs may hamper the growth of this market. Also, the expiry of patents of the major drugs and the huge cost and time factor that is involved in the drug discovery hamper the growth of the global drug discovery market.

North America leads the global market for drug discovery due to the presence of manufacturing and research facilities in the region; also, it is the largest consumer of the branded drugs. This region is most lucrative as large number of leading pharmaceutical company's presence. North America countries such as U.S. and Canada have formulated policies for encouraging investors for research in drug development and discovery. Asia Pacific market is driven by rise in the number contract research organizations. Asia-pacific is fastest growing region due to the presence of skilled labor at affordable cost, rise in disposable income and favorable government policies are also contributing in the market growth.

Global drug discovery market involves the process by which medications are discovered. These drugs are discovered by identifying the active ingredient by serendipitous discovery. The report scope of global drug discovery market covers segmentation analysis of drug type, technology, service and end-user. Drug type segment of global drug discovery market includes: small molecule drug and biologics drug. Technology segment of global drug discovery market includes: high throughput screening, biochips, bioinformatics, pharmacogenomics and pharmacogenetics, combinatorial chemistry, nanotechnology, spectroscopy, metabolomics and other technologies. Service segment of global drug discovery market includes: Drug Metabolism and Pharmacokinetics (DMPK) services, pharmaceutical services, chemical services and biological services. End-user segment of global drug discovery market includes: research institutes, pharmaceutical companies, biotechnology companies and other end users.

Major players present in the market includes Pfizer (U.S.), GlaxoSmithKline PLC (UK), Johnson and Johnson (U.S), Bayer (Germany) and others. Further, presence of these major players in the market is expected to increase the opportunity for innovation in the field of global drug discovery market. Mergers & acquisitions, product launches, etc. are the major strategies adopted for expansion of business in global drug discovery market.

TABLE OF CONTENTS

1.INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL DRUG DISCOVERY MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTER'S 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. PREVALENCE OF CHRONIC DISEASES
    • 3.1.2. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS
    • 3.1.3. INCREASING HEALTHCARE EXPENDITURE
    • 3.1.4. INCREASING DRUG APPROVALS BY GOVERNMENT ORGANIZATION
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. STRINGENT GOVERNMENT REGULATIONS
    • 3.2.2. HUGE CAPITAL INVESTMENT WITH LOW PROFIT MARGINS
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. ENHANCEMENT IN POPULATION OF AFFLUENT PATIENTS
    • 3.3.2. RISE IN DRUG DISCOVERY OUTSOURCING
  • 3.4. MARKET CHALLENGES
    • 3.4.1. HIGH AMOUNT OF INVESTMENT
    • 3.4.2. REQUIRES A LONG TIME SPAN

4. GLOBAL DRUG DISCOVERY MARKET BY DRUG TYPE

  • 4.1. MARKET DEFINITION AND SCOPE
  • 4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. MARKET SEGMENTATION
    • 4.5.1. GLOBAL SMALL MOLECULE DRUG MARKET
      • 4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.1.4. KEY CONCLUSIONS
    • 4.5.2. GLOBAL BIOLOGICS DRUG MARKET
      • 4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.2.4. KEY CONCLUSIONS

5. GLOBAL DRUG DISCOVERY MARKET BY TECHNOLOGY

  • 5.1. MARKET DEFINITION AND SCOPE
  • 5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 5.4. OPPORTUNITY MATRIX
  • 5.5. MARKET SEGMENTATION
    • 5.5.1. GLOBAL HIGH THROUGHPUT SCREENING MARKET
      • 5.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.1.4. KEY CONCLUSIONS
    • 5.5.2. GLOBAL BIOCHIPS MARKET
      • 5.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.2.4. KEY CONCLUSIONS
    • 5.5.3. GLOBAL BIOINFORMATICS MARKET
      • 5.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.3.4. KEY CONCLUSIONS
    • 5.5.4. GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET
      • 5.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.4.4. KEY CONCLUSIONS
    • 5.5.5. GLOBAL COMBINATORIAL CHEMISTRY MARKET
      • 5.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.5.4. KEY CONCLUSIONS
    • 5.5.6. GLOBAL NANOTECHNOLOGY MARKET
      • 5.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.6.4. KEY CONCLUSIONS
    • 5.5.7. GLOBAL SPECTROSCOPY MARKET
      • 5.5.7.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.7.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.7.4. KEY CONCLUSIONS
    • 5.5.8. GLOBAL METABOLOMICS MARKET
      • 5.5.8.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.8.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.8.4. KEY CONCLUSIONS
    • 5.5.9. GLOBAL OTHER TECHNOLOGIES MARKET
      • 5.5.9.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.9.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.9.4. KEY CONCLUSIONS

6. GLOBAL DRUG DISCOVERY MARKET BY SERVICE

  • 6.1. MARKET DEFINITION AND SCOPE
  • 6.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.4. OPPORTUNITY MATRIX
  • 6.5. MARKET SEGMENTATION
    • 6.5.1. GLOBAL DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET
      • 6.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.1.4. KEY CONCLUSIONS
    • 6.5.2. GLOBAL PHARMACEUTICAL SERVICES MARKET
      • 6.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.2.4. KEY CONCLUSIONS
    • 6.5.3. GLOBAL CHEMICAL SERVICES MARKET
      • 6.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.3.4. KEY CONCLUSIONS
    • 6.5.4. GLOBAL BIOLOGICAL SERVICES MARKET
      • 6.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.4.4. KEY CONCLUSIONS

7. GLOBAL DRUG DISCOVERY MARKET BY END USER

  • 7.1. MARKET DEFINITION AND SCOPE
  • 7.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 7.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 7.4. OPPORTUNITY MATRIX
  • 7.5. MARKET SEGMENTATION
    • 7.5.1. GLOBAL RESEARCH INSTITUTES MARKET
      • 7.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 7.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 7.5.1.4. KEY CONCLUSIONS
    • 7.5.2. GLOBAL PHARMACEUTICAL COMPANIES MARKET
      • 7.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 7.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 7.5.2.4. KEY CONCLUSIONS
    • 7.5.3. GLOBAL BIOTECHNOLOGY COMPANIES MARKET
      • 7.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 7.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 7.5.3.4. KEY CONCLUSIONS
    • 7.5.4. GLOBAL OTHER END USERS MARKET
      • 7.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 7.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 7.5.4.4. KEY CONCLUSIONS

8. COMPETITIVE LANDSCAPE

  • 8.1. KEY STRATEGIES
    • 8.1.1. LIST OF MERGER & ACQUISITION
    • 8.1.2. LIST OF JOINT VENTURE
    • 8.1.3. LIST OF PRODUCT LAUNCHES
    • 8.1.4. LIST OF PARTNERSHIP

9. GEOGRAPHIC ANALYSIS

  • 9.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 9.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 9.3. OPPORTUNITY MATRIX
  • 9.4. GLOBAL DRUG DISCOVERY MARKET BY REGION 2015-2024 ($ MILLION)
    • 9.4.1. NORTH AMERICA
      • 9.4.1.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 9.4.1.2. TOP COUNTRY ANALYSIS
        • 9.4.1.2.1. U.S.
          • 9.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.1.2.1.3. KEY CONCLUSIONS
        • 9.4.1.2.2. CANADA
          • 9.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.1.2.2.3. KEY CONCLUSIONS
    • 9.4.2. EUROPE
      • 9.4.2.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 9.4.2.2. TOP COUNTRY ANALYSIS
        • 9.4.2.2.1. UK
          • 9.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.2.2.1.3. KEY CONCLUSIONS
        • 9.4.2.2.2. FRANCE
          • 9.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.2.2.2.3. KEY CONCLUSIONS
        • 9.4.2.2.3. GERMANY
          • 9.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.2.2.3.3. KEY CONCLUSIONS
        • 9.4.2.2.4. RUSSIA
          • 9.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.2.2.4.3. KEY CONCLUSIONS
        • 9.4.2.2.5. REST OF EUROPE
          • 9.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.2.2.5.3. KEY CONCLUSIONS
    • 9.4.3. ASIA PACIFIC
      • 9.4.3.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 9.4.3.2. TOP COUNTRY ANALYSIS
        • 9.4.3.2.1. CHINA
          • 9.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.3.2.1.3. KEY CONCLUSIONS
        • 9.4.3.2.2. INDIA
          • 9.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.3.2.2.3. KEY CONCLUSIONS
        • 9.4.3.2.3. JAPAN
          • 9.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.3.2.3.3. KEY CONCLUSIONS
        • 9.4.3.2.4. AUSTRALIA
          • 9.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.3.2.4.3. KEY CONCLUSIONS
        • 9.4.3.2.5. REST OF ASIA PACIFIC
          • 9.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.3.2.5.3. KEY CONCLUSIONS
    • 9.4.4. ROW
      • 9.4.4.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 9.4.4.2. TOP COUNTRY ANALYSIS
        • 9.4.4.2.1. LATIN AMERICA
          • 9.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.4.2.1.3. KEY CONCLUSIONS
        • 9.4.4.2.2. MIDDLE EAST & AFRICA
          • 9.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 9.4.4.2.2.3. KEY CONCLUSIONS

10. COMPANY PROFILES

  • 10.1. ASTRAZENECA (U.K)
    • 10.1.1. OVERVIEW
    • 10.1.2. PRODUCT PORTFOLIO
    • 10.1.3. STRATEGIC INITIATIVES
    • 10.1.4. SCOT ANALYSIS
    • 10.1.5. STRATEGIC ANALYSIS
  • 10.2. ALBANY MOLECULER RESEARCH (U.S.)
    • 10.2.1. OVERVIEW
    • 10.2.2. PRODUCT PORTFOLIO
    • 10.2.3. STRATEGIC INITIATIVES
    • 10.2.4. SCOT ANALYSIS
    • 10.2.5. STRATEGIC ANALYSIS
  • 10.3. BAYER (GERMANY)
    • 10.3.1. OVERVIEW
    • 10.3.2. PRODUCT PORTFOLIO
    • 10.3.3. STRATEGIC INITIATIVES
    • 10.3.4. SCOT ANALYSIS
    • 10.3.5. STRATEGIC ANALYSIS
  • 10.4. BOEHRINGER INGELHEIM (GERMANY)
    • 10.4.1. OVERVIEW
    • 10.4.2. PRODUCT PORTFOLIO
    • 10.4.3. STRATEGIC INITIATIVES
    • 10.4.4. SCOT ANALYSIS
    • 10.4.5. STRATEGIC ANALYSIS
  • 10.5. COVANCE. (U.S.)
    • 10.5.1. OVERVIEW
    • 10.5.2. PRODUCT PORTFOLIO
    • 10.5.3. STRATEGIC INITIATIVES
    • 10.5.4. SCOT ANALYSIS
    • 10.5.5. STRATEGIC ANALYSIS
  • 10.6. CYPROTEX. (U.K.)
    • 10.6.1. OVERVIEW
    • 10.6.2. PRODUCT PORTFOLIO
    • 10.6.3. STRATEGIC INITIATIVES
    • 10.6.4. SCOT ANALYSIS
    • 10.6.5. STRATEGIC ANALYSIS
  • 10.7. ELI LILY (U.S)
    • 10.7.1. OVERVIEW
    • 10.7.2. PRODUCT PORTFOLIO
    • 10.7.3. STRATEGIC INITIATIVES
    • 10.7.4. SCOT ANALYSIS
    • 10.7.5. STRATEGIC ANALYSIS
  • 10.8. GLAXOSMITHKLINE PLC (UK)
    • 10.8.1. OVERVIEW
    • 10.8.2. PRODUCT PORTFOLIO
    • 10.8.3. STRATEGIC INITIATIVES
    • 10.8.4. SCOT ANALYSIS
    • 10.8.5. STRATEGIC ANALYSIS
  • 10.9. GENSCRIPT (U.S)
    • 10.9.1. OVERVIEW
    • 10.9.2. PRODUCT PORTFOLIO
    • 10.9.3. STRATEGIC INITIATIVES
    • 10.9.4. SCOT ANALYSIS
    • 10.9.5. STRATEGIC ANALYSIS
  • 10.10. JOHNSON AND JOHNSON (U.S)
    • 10.10.1. OVERVIEW
    • 10.10.2. PRODUCT PORTFOLIO
    • 10.10.3. STRATEGIC INITIATIVES
    • 10.10.4. SCOT ANALYSIS
    • 10.10.5. STRATEGIC ANALYSIS
  • 10.11. PFIZER, INC. (U.S.)
    • 10.11.1. OVERVIEW
    • 10.11.2. PRODUCT PORTFOLIO
    • 10.11.3. STRATEGIC INITIATIVES
    • 10.11.4. SCOT ANALYSIS
    • 10.11.5. STRATEGIC ANALYSIS
  • 10.12. QUINTILES (U.S)
    • 10.12.1. OVERVIEW
    • 10.12.2. PRODUCT PORTFOLIO
    • 10.12.3. STRATEGIC INITIATIVES
    • 10.12.4. SCOT ANALYSIS
    • 10.12.5. STRATEGIC ANALYSIS
  • 10.13. VIVA BIOTECH (CHINA)
    • 10.13.1. OVERVIEW
    • 10.13.2. PRODUCT PORTFOLIO
    • 10.13.3. STRATEGIC INITIATIVES
    • 10.13.4. SCOT ANALYSIS
    • 10.13.5. STRATEGIC ANALYSIS
  • 10.14. WIL RESEARCH LABORATORIES (U.S.)
    • 10.14.1. OVERVIEW
    • 10.14.2. PRODUCT PORTFOLIO
    • 10.14.3. STRATEGIC INITIATIVES
    • 10.14.4. SCOT ANALYSIS
    • 10.14.5. STRATEGIC ANALYSIS
  • 10.15. WUXI APPTECH (CHINA)
    • 10.15.1. OVERVIEW
    • 10.15.2. PRODUCT PORTFOLIO
    • 10.15.3. STRATEGIC INITIATIVES
    • 10.15.4. SCOT ANALYSIS
    • 10.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • 1. GLOBAL DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 2. GLOBAL SMALL MOLECULE DRUG MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 3. GLOBAL BIOLOGICS DRUG MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 4. GLOBAL DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 5. GLOBAL HIGH THROUGHPUT SCREENING MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 6. GLOBAL BIOCHIPS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 7. GLOBAL BIOINFORMATICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 8. GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 9. GLOBAL COMBINATORIAL CHEMISTRY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 10. GLOBAL NANOTECHNOLOGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 11. GLOBAL SPECTROSCOPY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 12. GLOBAL METABOLOMICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 13. GLOBAL OTHER TECHNOLOGIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 14. GLOBAL DRUG DISCOVERY MARKET BY SERVICE 2015-2024 ($ MILLION)
  • 15. GLOBAL DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 16. GLOBAL PHARMACEUTICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 17. GLOBAL CHEMICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 18. GLOBAL BIOLOGICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 19. GLOBAL DRUG DISCOVERY MARKET BY END USER 2015-2024 ($ MILLION)
  • 20. GLOBAL RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 21. GLOBAL PHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 22. GLOBAL BIOTECHNOLOGY COMPANIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 23. GLOBAL OTHER END USERS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 24. NORTH AMERICA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 25. EUROPE DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 26. ASIA PACIFIC DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 27. REST OF THE WORLD DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 28. NORTH AMERICA DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 29. EUROPE DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 30. ASIA PACIFIC DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 31. REST OF THE WORLD DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 32. NORTH AMERICA DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 33. EUROPE DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 34. ASIA PACIFIC DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 35. REST OF THE WORLD DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 36. NORTH AMERICA DRUG DISCOVERY MARKET BY SERVICE 2015-2024 ($ MILLION)
  • 37. EUROPE DRUG DISCOVERY MARKET BY SERVICE2015-2024 ($ MILLION)
  • 38. ASIA PACIFIC DRUG DISCOVERY MARKET BY SERVICE 2015-2024 ($ MILLION)
  • 39. REST OF THE WORLD DRUG DISCOVERY MARKET BY SERVICE 2015-2024 ($ MILLION)
  • 40. UNITED STATES GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 41. UNITED STATES GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 42. UNITED STATES GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 43. UNITED STATES GLOBAL DRUG DISCOVERY BY END USER 2015-2024 ($ MILLION)
  • 44. CANADA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 45. CANADA GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 46. CANADA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 47. CANADA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 48. UK GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 49. UK GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 50. UK GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 51. UK GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 52. GERMANY GLOBAL DRUG DISCOVERY BY DRUG TYPE 2015-2024 ($ MILLION)
  • 53. GERMANY GLOBAL DRUG DISCOVERY BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 54. GERMANY GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 55. GERMANY GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 56. FRANCE GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 57. FRANCE GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 58. FRANCE GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 59. FRANCE GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 60. SPAIN GLOBAL DRUG DISCOVERY BY DRUG TYPE 2015-2024 ($ MILLION)
  • 61. SPAIN GLOBAL DRUG DISCOVERY BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 62. SPAIN GLOBAL DRUG DISCOVERY BY SERVICE 2015-2024 ($ MILLION)
  • 63. SPAIN GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 64. ROE GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 65. ROE GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 66. ROE GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 67. ROE GLOBAL DRUG DISCOVERYBY END USER TYPE 2015-2024 ($ MILLION)
  • 68. INDIA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 69. INDIA GLOBAL DRUG DISCOVERY TECHNOLOGY 2015-2024 ($ MILLION)
  • 70. INDIA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 71. INDIA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 72. CHINA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 73. CHINA GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 74. CHINA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 75. CHINA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 76. JAPAN GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 77. JAPAN GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 78. JAPAN GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 79. JAPAN GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 80. AUSTRALIA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 81. AUSTRALIA GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 82. AUSTRALIA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 83. AUSTRALIA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 84. ROAPAC GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 85. ROAPAC GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 86. ROAPAC GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 87. ROAPAC GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 88. LATIN AMERICA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 89. LATIN AMERICA GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 90. LATIN AMERICA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 91. LATIN AMERICA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)
  • 92. MENA GLOBAL DRUG DISCOVERYBY DRUG TYPE 2015-2024 ($ MILLION)
  • 93. MENA GLOBAL DRUG DISCOVERYBY TECHNOLOGY 2015-2024 ($ MILLION)
  • 94. MENA GLOBAL DRUG DISCOVERYBY SERVICE 2015-2024 ($ MILLION)
  • 95. MENA GLOBAL DRUG DISCOVERYBY END USER 2015-2024 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DRUG DISCOVERY MARKET BY DRUG TYPE 2015-2024 ($ MILLION)
  • 2. GLOBAL SMALL MOLECULE DRUG MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 3. GLOBAL BIOLOGICS DRUG MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 4. GLOBAL DRUG DISCOVERY MARKET BY TECHNOLOGY 2015-2024 ($ MILLION)
  • 5. GLOBAL HIGH THROUGHPUT SCREENING MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 6. GLOBAL BIOCHIPS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 7. GLOBAL BIOINFORMATICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 8. GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 9. GLOBAL COMBINATORIAL CHEMISTRY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 10. GLOBAL NANOTECHNOLOGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 11. GLOBAL SPECTROSCOPY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 12. GLOBAL METABOLOMICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 13. GLOBAL OTHER TECHNOLOGIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 14. GLOBAL DRUG DISCOVERY MARKET BY SERVICE 2015-2024 ($ MILLION)
  • 15. GLOBAL DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 16. GLOBAL PHARMACEUTICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 17. GLOBAL CHEMICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 18. GLOBAL BIOLOGICAL SERVICES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 19. GLOBAL DRUG DISCOVERY MARKET BY END USER 2015-2024 ($ MILLION)
  • 20. GLOBAL RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 21. GLOBAL PHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 22. GLOBAL BIOTECHNOLOGY COMPANIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 23. GLOBAL OTHER END USERS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 24. UNITED STATES (U.S.) DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 25. CANADA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 26. UNITED KINGDOM (UK) DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 27. FRANCE DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 28. GERMANY DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 29. RUSSIA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 30. ROE DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 31. INDIA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 32. CHINA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 33. JAPAN DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 34. AUSTRALIA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 35. ROAPAC DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 36. LATIN AMERICA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
  • 37. MENA DRUG DISCOVERY MARKET 2015-2024 ($ MILLION)
Back to Top